WO2026130514 - COMBINATION AND METHOD THEREOF FOR TREATING LIPID DISORDERS
National phase entry is expected:
Publication Number
WO/2026/130514
Publication Date
25.06.2026
International Application No.
PCT/CN2025/143837
International Filing Date
19.12.2025
Title **
[English]
COMBINATION AND METHOD THEREOF FOR TREATING LIPID DISORDERS
[French]
COMBINAISON ET MÉTHODE ASSOCIÉE POUR LE TRAITEMENT DES TROUBLES LIPIDIQUES
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
LU, Mingjian
Priority Data
PCT/CN2024/141252
21.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3979 | |
| EPO | Filing, Examination, Granting | 32725 | |
| Japan | Filing, Examination, Granting | 3172 | |
| South Korea | Filing, Examination, Granting | 4288 | |
| USA | Filing, Examination, Granting | 11690 |
Total:
55,854
Contact Us
Abstract[English]
Combinations and methods that can be used to treat lipid disorders are provided. Provided are combinations comprising HMGCR dsRNA agents and non-HMGCR dsRNA therapeutic agents that can be used to treat lipid disorders in subjects. Provided are methods comprising administering HMGCR dsRNA agents and non-HMGCR dsRNA therapeutic agents to treat lipid disorders in subjects.[French]
Des combinaisons et des méthodes pouvant être utilisées pour traiter des troubles lipidiques sont fournies. Sont fournies des combinaisons comprenant des agents ARNdb HMGCR et des agents thérapeutiques ARNdb non-HMGCR pouvant être utilisées pour traiter des troubles lipidiques chez des sujets. Sont fournies des méthodes comprenant l'administration d'agents ARNdb HMGCR et d'agents thérapeutiques ARNdb non-HMGCR pour traiter des troubles lipidiques chez des sujets.